NASDAQ · LPCN
Healthcare · Biotechnology
$2.16
Up+$0.06 (+2.78%)
Updated Sep 17, 2026, 9:34 PM
SID Score
3.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
LPCN closed at $2.16 after 20 trading sessions, up 5.37% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $2.23 | $2.235 | $2.15 | $2.16 | 64.03K |
| Sep 15, 2026 | $2.20 | $2.24 | $2.15 | $2.185 | 50.45K |
| Sep 14, 2026 | $2.20 | $2.2699 | $2.15 | $2.22 | 27.32K |
| Sep 11, 2026 | $2.29 | $2.30 | $2.25 | $2.27 | 10.4K |
| Sep 10, 2026 | $2.315 | $2.345 | $2.25 | $2.25 | 9.39K |
| Sep 9, 2026 | $2.34 | $2.3525 | $2.25 | $2.25 | 4.81K |
| Sep 8, 2026 | $2.39 | $2.40 | $2.345 | $2.36 | 21.14K |
| Sep 4, 2026 | $2.4206 | $2.4799 | $2.3612 | $2.45 | 23.18K |
| Sep 3, 2026 | $2.41 | $2.50 | $2.32 | $2.42 | 26.67K |
| Sep 2, 2026 | $2.22 | $2.39 | $2.22 | $2.355 | 35.05K |
| Sep 1, 2026 | $2.19 | $2.30 | $2.1831 | $2.30 | 10.02K |
| Aug 31, 2026 | $2.14 | $2.29 | $2.14 | $2.24 | 27.53K |
| Aug 28, 2026 | $2.23 | $2.23 | $2.13 | $2.17 | 19.55K |
| Aug 27, 2026 | $2.17 | $2.30 | $2.17 | $2.23 | 41.55K |
| Aug 26, 2026 | $2.15 | $2.29 | $2.15 | $2.15 | 106.05K |
| Aug 25, 2026 | $2.08 | $2.16 | $2.07 | $2.15 | 11.79K |
| Aug 24, 2026 | $2.07 | $2.10 | $2.0501 | $2.06 | 26.73K |
| Aug 21, 2026 | $2.11 | $2.11 | $2.06 | $2.09 | 18.22K |
| Aug 20, 2026 | $2.05 | $2.1349 | $2.05 | $2.09 | 35.16K |
| Aug 19, 2026 | $2.105 | $2.115 | $2.05 | $2.05 | 24.87K |
The latest Smart Investors Daily articles mentioning LPCN.
LPCN research
Company profile and research snapshot.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 6, 2026 | HC Wainwright & Co. | Neutral | — |
| Jan 21, 2026 | HC Wainwright & Co. | Buy | — |
| Nov 13, 2025 | HC Wainwright & Co. | Buy | — |
| Aug 20, 2025 | HC Wainwright & Co. | Buy | — |
| Jun 27, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 10, 2026
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that Company management will present and meet with investors at the H.C. Wainwright 28th Annual Global Investment Conference, to be held in person and virtually September 14-16, 2026.
Yahoo · Aug 4, 2026
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced financial results for the second quarter ended June 30, 2026 and provided a corporate update.
Benzinga · Aug 4, 2026
Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.43) by 25.58 percent. This is a 21.95 percent increase over losses of $(0.41) per share from the
Yahoo · Aug 3, 2026
Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced the appointment of Michael J. Grissinger to its Board of Directors, effective August 3, 2026.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning LPCN.
